Comparison of the anesthetic effects of remimazolam tosilate and remimazolam besylate in daytime hysteroscopic surgery.
Day surgery
Remimazolam besylate
Remimazolam tosilate
Journal
BMC anesthesiology
ISSN: 1471-2253
Titre abrégé: BMC Anesthesiol
Pays: England
ID NLM: 100968535
Informations de publication
Date de publication:
23 Oct 2024
23 Oct 2024
Historique:
received:
13
08
2024
accepted:
17
10
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
epublish
Résumé
The purpose of this study is to observe whether there is a difference in the anesthetic effect of remimazolam tosilate and remimazolam besylate in daytime hysteroscopic surgery, so as to provide reference for clinical application. Fifty patients, aged 18-65 years, ASA I-II, scheduled for hysteroscopy under total intravenous anesthesia were selected. The patients were randomly divided into two groups (n = 25): remimazolam tosilate group (group T) and remimazolam besylate group ( group R). The main observation index was the induction dose of remimazolam; secondary observation indicators were sleep time, anesthesia maintenance time, recovery time, induction maintenance dose of alfentanil, maintenance dose of remimazolam, and incidence of adverse events during anesthesia ( hypertension, hypotension, bradycardia, tachycardia). There was no significant difference in anesthesia induction dose, recovery time, sleep time, anesthesia maintenance time, and incidence of adverse events during anesthesia ( body movement, cough, hypertension, hypotension, bradycardia, tachycardia) between the two groups (P > 0.05). There was no significant difference in the anesthetic effect of remimazolam tosilate and remimazolam besylate in daytime hysteroscopic surgery. Chinese Clinical Trial Registry, ChiCTR2400081688.
Identifiants
pubmed: 39443850
doi: 10.1186/s12871-024-02773-6
pii: 10.1186/s12871-024-02773-6
doi:
Substances chimiques
remimazolam
7V4A8U16MB
Benzodiazepines
12794-10-4
Hypnotics and Sedatives
0
Alfentanil
1N74HM2BS7
Types de publication
Journal Article
Randomized Controlled Trial
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
382Informations de copyright
© 2024. The Author(s).
Références
Schüttler J, Eisenried A, Lerch M, et al. Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers: Part I Pharmacokinetics and Clinical Pharmacodynamics. Anesthesiology. 2020;132(4):636–51. https://doi.org/10.1097/ALN.0000000000003103 .
doi: 10.1097/ALN.0000000000003103
pubmed: 31972655
Masui K. Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia. J Anesth. 2020;34(4):479–82. https://doi.org/10.1007/s00540-020-02755-1 .
doi: 10.1007/s00540-020-02755-1
pubmed: 32157465
Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056: a novel ultra-short-acting Benzodiazepine. Anesthesiology. 2007;107(1):60–6.
doi: 10.1097/01.anes.0000267503.85085.c0
pubmed: 17585216
Antonik LJ, Goldwater DR, Kilpatrick GJ, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2012;115(2):274–83.
doi: 10.1213/ANE.0b013e31823f0c28
pubmed: 22190555
Goudra BG, Singh PM. Remimazolam: The future of its sedative potential. Saudi J Anaesth. 2014;8(3):388–91. https://doi.org/10.4103/1658-354X.136627 .
doi: 10.4103/1658-354X.136627
pubmed: 25191193
pmcid: 4141391
Roozekrans M, van der Schrier R, Aarts L, et al. Benefit versus Severe Side Effects of Opioid Analgesia: Novel Utility Functions of Probability of Analgesia and Respiratory Depression. Anesthesiology. 2018;128(5):932–42. https://doi.org/10.1097/ALN.0000000000002138 .
doi: 10.1097/ALN.0000000000002138
pubmed: 29498950
Li H, Zhang H, Cheng Z, et al. Effects of alfentanil hydrochloride on cough and hemodynamics during induction of general anesthesia in daytime surgery [published online ahead of print, 2022 Jan 28]. Minerva Surg. 2022; https://doi.org/10.23736/S2724-5691.21.09341-2 .
Zhao N, Zeng J, Fan L, et al. Moderate sedation by total intravenous remimazolam-alfentanil vs. propofol-alfentanil for third molar extraction: A prospective randomized controlled trial. Front Med (Lausanne). 2022;9:950564. https://doi.org/10.3389/fmed.2022.950564 . Published 2022 Sep 2.
doi: 10.3389/fmed.2022.950564
pubmed: 36117971
Zhang S, Wang J, Ran R, Peng Y, Xiao Y. Efficacy and safety of remimazolam tosylate in hysteroscopy: A randomized, single-blind, parallel controlled trial. J Clin Pharm Ther. 2022;47(1):55–60. https://doi.org/10.1111/jcpt.13525 .
doi: 10.1111/jcpt.13525
pubmed: 34655087
Zhang X, Li S, Liu J. Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial [published correction appears in BMC Anesthesiol. 2021;21(1):173]. BMC Anesthesiol. 2021;21(1):156. Published 2021 May 20. https://doi.org/10.1186/s12871-021-01373-y.
Tang F, Yi JM, Gong HY, et al. Remimazolam benzenesulfonate anesthesia effectiveness in cardiac surgery patients under general anesthesia. World J Clin Cases. 2021;9(34):10595–603. https://doi.org/10.12998/wjcc.v9.i34.10595 .
doi: 10.12998/wjcc.v9.i34.10595
pubmed: 35004991
pmcid: 8686148
Shi F, Chen Y, Li H, Zhang Y, Zhao T. Efficacy and Safety of Remimazolam Tosilate versus Propofol for General Anesthesia in Cirrhotic Patients Undergoing Endoscopic Variceal Ligation. Int J Gen Med. 2022;15:583–91. https://doi.org/10.2147/IJGM.S345390 . Published 2022 Jan 13.
doi: 10.2147/IJGM.S345390
pubmed: 35046716
pmcid: 8763269
Chen X, Sang N, Song K, et al. Psychomotor Recovery Following Remimazolam-induced Sedation and the Effectiveness of Flumazenil as an Antidote. Clin Ther. 2020;42(4):614–24. https://doi.org/10.1016/j.clinthera.2020.02.006 .
doi: 10.1016/j.clinthera.2020.02.006
pubmed: 32178858